Dr. Rini Describes Hypertension as a Biomarker

Lead investigator Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at Cleveland Clinic in Ohio, explains results from the AXIS 1032 phase III trial comparing axitinib to sorafenib in the second-line setting for metastatic renal cell carcinoma (mRCC). Retrospective data from the study indicated hypertension as a marker of superior outcome.